Mesenchymal Stem Cell Derived Exosomes - Buddhadeb Dawn, Yaoliang Tang

Mesenchymal Stem Cell Derived Exosomes (eBook)

The Potential for Translational Nanomedicine

Buddhadeb Dawn, Yaoliang Tang (Autoren)

eBook Download: PDF | EPUB

2015 | 1. Auflage
288 Seiten
Elsevier Science (Verlag)
978-0-12-800497-5 (ISBN)

Mesenchymal stem cell-derived exosomes are at the forefront of research in two of the most high profile and funded scientific areas - cardiovascular research and stem cells. Mesenchymal Stem Cell Derived Exosomes provides insight into the biofunction and molecular mechanisms, practical tools for research, and a look toward the clinical applications of this exciting phenomenon which is emerging as an effective diagnostic. Primarily focused on the cardiovascular applications where there have been the greatest advancements toward the clinic, this is the first compendium for clinical and biomedical researchers who are interested in integrating MSC-derived exosomes as a diagnostic and therapeutic tool. - Introduces the MSC-exosome mediated cell-cell communication - Covers the major functional benefits in current MSC-derived exosome studies - Discusses strategies for the use of MSC-derived exosomes in cardiovascular therapies

Mesenchymal stem cell-derived exosomes are at the forefront of research in two of the most high profile and funded scientific areas - cardiovascular research and stem cells. Mesenchymal Stem Cell Derived Exosomes provides insight into the biofunction and molecular mechanisms, practical tools for research, and a look toward the clinical applications of this exciting phenomenon which is emerging as an effective diagnostic. Primarily focused on the cardiovascular applications where there have been the greatest advancements toward the clinic, this is the first compendium for clinical and biomedical researchers who are interested in integrating MSC-derived exosomes as a diagnostic and therapeutic tool. - Introduces the MSC-exosome mediated cell-cell communication- Covers the major functional benefits in current MSC-derived exosome studies- Discusses strategies for the use of MSC-derived exosomes in cardiovascular therapies

Chapter 2

An Overview of the Proteomic and miRNA Cargo in MSC-Derived Exosomes

Soon Sim Tan*

Tian Sheng Chen**

Kok Hian Tan†

Sai Kiang Lim*,‡
*    Department of Surgery, Institute of Medical Biology, A*STAR, YLL School of Medicine, NUS, Singapore
**    College of Fisheries, Huazhong Agricultural University, Wuhan, Hubei Province, P.R. China
†    Department of Maternal Fetal Medicine, KK Women’s and Children’s Hospital, Singapore
‡    Department of Surgery, YLL School of Medicine, NUS, Singapore

Abstract

Mesenchymal stem cells (MSCs) exert part of their therapeutic efficacy through exosomes present in their secretions. MSC exosomes are bilipid membrane vesicles that contain both proteins and RNAs. Analysis of the proteomic and RNA cargo of the MSC exosome by high-throughput assays such as mass spectrometry, antibody arrays, and DNA probe arrays revealed an abundance of miRNAs and proteins. The miRNAs and proteins in the exosomes represent a select fraction of miRNAs and proteins in MSCs. In addition, the exosomal miRNAs, unlike cellular miRNAs, are highly enriched in pre-miRNAs while the proteins are functionally clustered in several processes. Together, the selective composition of RNAs and proteins in MSC exosomes demonstrates that MSC exosome biogenesis is a highly regulated and therefore important process. Moreover, this selective RNA and protein composition could provide an insight into the molecular targets of MSC exosome-mediated therapy.

Keywords

proteomic

miRNA

exosome

mesenchymal stem cells

secretion

Contents

1 Background 21

1.1 Mesenchymal Stem Cells 21

1.2 Mechanism of Action of MSCs: Paracrine Secretion 22

1.3 Secreted MSC Mediators 22

1.4 Active Agent in MSC Secretion: Exosome 23

2 Cargo of MSC Exosomes 24

2.1 RNA Cargo of MSC Exosomes 25

2.2 Proteome of MSC Exosomes 26

2.2.1 Computational Analysis of the MSC Exosome Proteome 28

2.2.2 Biochemical Activity of the MSC Proteome 29

2.2.3 Enzymes 29

2.2.4 Inhibitors 31

2.2.5 Immune Modulators 31

3 Conclusions 31

References 32

1. Background

1.1. Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) were first described in 1968 as multipotent fibroblast-like cells from bone marrow [1] with a potential to differentiate into osteocytes, chondrocytes, adipocytes, and myoblasts [2,3]. MSCs have now been isolated from diverse sources of tissues such adipose tissue [4,5], liver [6], muscle [7], amniotic fluid [8], placenta [9,10], umbilical cord blood [4], dental pulp [11,12], and other sources [6,13]. Despite the difference in tissue sources, MSCs share several common characteristics: plastic adherence, expression of CD105, CD73, and CD90 but not CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR surface molecules, and an in vitro differentiation potential of osteogenesis, adipogenesis, and chondrogenesis [14].

MSCs are currently the most evaluated stem cells with more than 118 registered clinical trials (http://www.clinicaltrials.gov/, January 2014). The attractiveness of MSCs could be attributed to their regenerative potential, ease of isolation from adult tissues such as bone marrow and adipose tissue, and a large ex vivo expansion capacity (reviewed in [15–17]).

1.2. Mechanism of Action of MSCs: Paracrine Secretion

The use of MSCs as therapeutics was predicated on the hypothetical potential of transplanted MSCs to home in engraft and differentiate to repair injured tissues. However, it has been estimated that <1% of transplanted cells actually reached the target tissue with most of the cells being trapped in the liver, spleen, and lung [18] and few of the appropriately homed and engrafted cells demonstrated unambiguous evidence of differentiation [19–21]. Instead, the therapeutic efficacy of MSC therapy was observed to be independent of the engraftment or differentiation of transplanted MSCs at the site of injury [22–26]. Hence, it was proposed that MSCs exert their therapeutic effects through the secretion of growth factors and cytokines [27]. This proposal provides for a more all-encompassing mechanism of action for MSC efficacy in a wide range of disease indications and injuries [28–35].

1.3. Secreted MSC Mediators

The search for soluble mediators of MSC therapy has focused initially on chemokines, cytokines, or secreted proteins. For example, MSC that was approved for treatment of pediatric graft-versus-host disease in Canada and New Zealand was postulated to modulate regulatory T cells or Tregs, a subpopulation of T cells through the secretion of soluble mediators known to enhance Treg expansion. Many candidates such as transforming growth factor beta, prostaglandin E2, human leukocyte antigen G, interleukin-10, and indoleamine-pyrrole 2,3-dioxygenase were proposed (reviewed in [36]). However, none of the soluble mediators identified to date was sufficient in mediating the MSC immune modulatory effect [37].

To conduct an unbiased search for a secreted mediator, we took a first principle approach by profiling the proteome of MSC secretion, which is essentially culture medium conditioned by MSC. At that time, proteomic analysis of MSC-conditioned culture medium was not amenable to high-throughput unbiased mass spectrometry as MSC culture was still dependent on serum, which contains high abundance serum proteins such as albumin and immunoglobulins that obscure the detection of low abundance secreted proteins. To circumvent this, MSCs were cultured for 3 days in serum-free Dulbecco’s modified eagle’s medium supplemented with five peptides, namely insulin, transferrin, selenoprotein, fibroblast growth factor 2 with bovine serum albumin carrier, and platelet-derived growth factor AB [38]. Under this culture condition, MSCs remain viable for at least a week and when returned to serum-containing medium, they regain their proliferative activity without significant loss in their differentiation potential (unpublished observation). Using this defined medium, the conditioned medium (CM) was highly amenable to sensitive unbiased high-throughput mass spectrometry analysis to elucidate MSC secretome. As mass spectrometry is relatively insensitive in detecting small peptides such as cytokines, chemokines, and growth factors, mass spectrometry analysis was complemented with commercially available antibody arrays to detect small proteins that had commercially available antibodies. Using these two different analytical approaches, we detected 201 proteins secreted by MSCs. Of the 33 proteins that were previously reported to be secreted by MSCs, 29 proteins were present in the 201 proteins leaving 172 of the 201 proteins not known to be secreted by MSCs [38]. Among the 172 proteins, a significant proportion was cytoplasmic proteins that were not known to be secreted. Based on this proteome, we hypothesized that MSC-conditioned culture medium could be cardioprotective [38]. This was confirmed in a pig and mouse model of acute myocardial ischemia/reperfusion injury from [39] and a pig model of chronic myocardial ischemia [40].

1.4. Active Agent in MSC Secretion: Exosome

To identify the active therapeutic agent/s in the complex MSC secretion, we first estimated the size range of the agent by ultrafiltration using membranes with different pore sizes, and then testing the filtrate or retentate for cardioprotective activity. Using this method, we established the size range of the active agent as 50–200 ηm, which was then confirmed visually by electron microscopy [39,41]. Subsequent biochemical and biophysical analysis identified these agents as lipid membrane vesicles with a detergent-sensitive flotation density range of 1.10–1.18 g/mL in sucrose, enriched in exosome-associated protein markers such as CD9, CD81, and Alix, and membrane lipids such as cholesterol, sphingomyelin, and phosphatidylcholine [41].

When these membrane vesicles were isolated by size exclusion high performance liquid chromatography (HPLC), they constituted a population of homogeneously sized particles with a hydrodynamic radius of 55–65 ηm and were as efficacious as CM in reducing infarct size in a mouse model. Therefore, the cardioprotective agent in MSC secretion is an exosome. Following our report, exosomes were implicated as the agent mediating the biological activity of MSCs in attenuating type 1 diabetes and multiple myeloma progression [42,43].

2. Cargo of MSC Exosomes

The implication of exosome as the active agent underpinning therapeutic efficacy of MSC converts MSC-based...

Erscheint lt. Verlag	2.9.2015
Sprache	englisch
Themenwelt	Medizin / Pharmazie ► Allgemeines / Lexika
	Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie
	Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie
	Studium ► 2. Studienabschnitt (Klinik) ► Anamnese / Körperliche Untersuchung
	Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
	Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung
	Naturwissenschaften ► Biologie ► Biochemie
	Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie
	Naturwissenschaften ► Biologie ► Zellbiologie
	Technik ► Umwelttechnik / Biotechnologie
	Wirtschaft
ISBN-10	0-12-800497-5 / 0128004975
ISBN-13	978-0-12-800497-5 / 9780128004975

Haben Sie eine Frage zum Produkt?

PDF (Adobe DRM)
Größe: 6,2 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

EPUB (Adobe DRM)

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Print-Ausgabe

Buch | Hardcover

92,25 €